Abstract
Objective: To investigate the pharmacokinetics of drospirenone (DRSP) and ethinylestradiol (EE) in Caucasian and Japanese women. Method: Three open-label, non-randomised studies were performed to assess the pharmacokinetics following single doses of EE 0.02 mg/DRSP 3 mg or DRSP monotherapy (1, 3 or 6 mg) in Caucasian (Study 1) and Japanese (Study 2) women, and daily doses with EE 0.02 mg/DRSP 3 mg over 21 consecutive days in Caucasian and Japanese women (Study 3). Results: In Studies 1 and 2, there was a linear dose-dependent increase in DRSP Cmax and systemic exposure across the range of doses used in both ethnic groups. The co- administration of EE had no relevant effect on the pharmacokinetic parameters of 3 mg DRSP. In Study 3, steady-state DRSP concentrations were achieved after about eight days of treatment in both ethnic groups with approximately a threefold accumulation. There was about a twofold EE accumulation over 21 days in both ethnic groups. There were no differences in DRSP or EE exposure at day 21 between ethnic groups; the ratio of the geometric means (Japanese/Caucasian) of the AUC0-24h were 1.05 (90% CI: 0.95-1.17) and 1.02 (90% CI: 0.76-1.38), respectively. Conclusion: Ethnic origin had no clinically relevant influence on the pharmacokinetics of DRSP and EE. © 2012 The European Society of Contraception and Reproductive Health.
Author supplied keywords
Cite
CITATION STYLE
Blode, H., Kowal, K., Roth, K., & Reif, S. (2012). Pharmacokinetics of drospirenone and ethinylestradiol in Caucasian and Japanese women. European Journal of Contraception and Reproductive Health Care, 17(4), 284–297. https://doi.org/10.3109/13625187.2012.677076
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.